IPO Advisory
In-depth, experienced and seamless execution throughout the IPO Process.
Chemkart India IPO is a Book Building listing on BSE SME exchange. The company is based in Mumbai and caters to Healthcare sector. Smart Horizon Capital Advisors is the merchant banker of Chemkart India IPO. It is a SME Upcoming IPO which filed its Draft Red Herring Prospectus (DRHP) on 25th March 2025.
Chemkart India IPO posted revenues of ₹ 228.86 crores and PAT of ₹ 29.46 crores in FY25 on annualised basis.
Revenue:
₹ 228.86 Cr.
EBITDA Margin:
17.49 % 
Net Worth: ₹ 43.76 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Financial results of Chemkart India IPO based on restated financials as per prospectus and IPO review parameters can be referred to below.
Chemkart India IPO PAT Margin is 12.87 % , ROCE (Return on Capital Employed) is 0.32 % as per latest financial. The below table shows Chemkart India IPO Key Performance Indicators (KPI) as mentioned in company’s prospectus.
The market Capitalisation of Chemkart India IPO is ₹ [●] crores at the time of IPO and other IPO valuation metrics of this IPO is mentioned below.
The Chemkart India IPO prospectus highlights an Return on Equity (ROE) of 15 %, Return on Assets (ROA) of 12 %, and an EBITDA Margin of 18 %, showcasing financial performance.
Profitability ratios like Return on Equity (ROE), Return on Assets (ROA), and Net Profit Margin shows Chemkart India IPO financial report. Analysing these metrics can provide insights into the company’s efficiency, profitability, and long-term growth potential.
The post-IPO market capitalisation of Chemkart India IPO is ₹ [●] Cr., based on the issue price and share structure. It helps investors gauge the company’s valuation and compare it with industry peers before investing.
The Chemkart India IPO has a Price-to-Earnings (PE) ratio of [●], indicating valuation compared to industry peers. It helps investors determine if the stock is overvalued or undervalued compared to its earnings and industry peers.
Chemkart India IPO reported revenue of ₹ 228.86 Cr. in the latest fiscal year, showing business performance, on annualised basis. Revenue figures from Chemkart India IPO provide insights into sales growth, market demand, and business scalability.
Chemkart India recorded an EBITDA of ₹ 40.02 Cr., reflecting operational efficiency. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortisation) measures operational profitability.
Chemkart India Profit After Tax (PAT) is ₹ 29.46 Cr., reflecting earnings growth. Profit After Tax (PAT) reflects the company’s actual earnings after all expenses, taxes, and deductions
Revenue:
₹ 228.86 Cr.
EBITDA Margin:
17.49
%
Net Worth: ₹ 43.76 Cr.
Market Capitalisation:
[●]
P/E:
[●]
P/BV: [●]
EV/EBITDA: [●]
Chemkart India operates in Healthcare and Health And Sports Supplement Products. The Issue is listed on BSE SME in Apr, 2025. Chemkart India IPO size was with Issue price of .
Merchant Banker(s) of Chemkart India IPO: Smart Horizon Capital Advisors Private Limited
Chemkart India IPO subscription was X. IPO subscription refers to applications received in an IPO by each quota, i.e., QIB, Retail, and NII. In some IPOs, Eligible employee quota and shareholder’s quota are also present. Learn more about IPO subscriptions here.
Chemkart India IPO listed at a listing price of against the offer price of .
The current market price of Chemkart India is .
Why Us?
